These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 36702387)
1. Injectable rhein-assisted crosslinked hydrogel for efficient local osteosarcoma chemotherapy. Zhang L; Liu YX; Yao YT; Zhou TJ; Jiang HL; Li CJ Int J Pharm; 2023 Mar; 634():122637. PubMed ID: 36702387 [TBL] [Abstract][Full Text] [Related]
2. In situ Co-Delivery of Doxorubicin and Cisplatin by Injectable Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment. Si M; Xia Y; Cong M; Wang D; Hou Y; Ma H Int J Nanomedicine; 2022; 17():1309-1322. PubMed ID: 35345787 [TBL] [Abstract][Full Text] [Related]
3. Injectable thermosensitive black phosphorus nanosheet- and doxorubicin-loaded hydrogel for synergistic bone tumor photothermal-chemotherapy and osteogenesis enhancement. Li S; Qing Y; Lou Y; Li R; Wang H; Wang X; Ying B; Tang X; Qin Y Int J Biol Macromol; 2023 Jun; 239():124209. PubMed ID: 36972826 [TBL] [Abstract][Full Text] [Related]
4. Doxorubicin and CD‑CUR inclusion complex co‑loaded in thermosensitive hydrogel PLGA‑PEG‑PLGA localized administration for osteosarcoma. Yang Z; Liu J; Lu Y Int J Oncol; 2020 Aug; 57(2):433-444. PubMed ID: 32468050 [TBL] [Abstract][Full Text] [Related]
6. CPPs-modified chitosan as permeability-enhancing chemotherapeutic combined with gene therapy nanosystem by thermosensitive hydrogel for the treatment of osteosarcoma. Cao J; Zhu C; Cao Z; Ke X Int J Biol Macromol; 2024 May; 267(Pt 2):130915. PubMed ID: 38561118 [TBL] [Abstract][Full Text] [Related]
7. PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment. Ma H; He C; Cheng Y; Li D; Gong Y; Liu J; Tian H; Chen X Biomaterials; 2014 Oct; 35(30):8723-34. PubMed ID: 25017095 [TBL] [Abstract][Full Text] [Related]
8. Injectable Magnetic Hydrogel Filler for Synergistic Bone Tumor Hyperthermia Chemotherapy. Hu P; Lu J; Li C; He Z; Wang X; Pan Y; Zhao L ACS Appl Bio Mater; 2024 Mar; 7(3):1569-1578. PubMed ID: 38349029 [TBL] [Abstract][Full Text] [Related]
9. The effect of PLGA-based hydrogel scaffold for improving the drug maximum-tolerated dose for in situ osteosarcoma treatment. Yang Z; Yu S; Li D; Gong Y; Zang J; Liu J; Chen X Colloids Surf B Biointerfaces; 2018 Dec; 172():387-394. PubMed ID: 30193198 [TBL] [Abstract][Full Text] [Related]
10. IL-11Rα-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma. Jiang J; Wang R; Yang L; Sha Y; Zhao S; Guo J; Chen D; Zhong Z; Meng F J Control Release; 2022 Oct; 350():460-470. PubMed ID: 36041590 [TBL] [Abstract][Full Text] [Related]
11. Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma. Liu Y; Raina DB; Sebastian S; Nagesh H; Isaksson H; Engellau J; Lidgren L; Tägil M Acta Biomater; 2021 Sep; 131():555-571. PubMed ID: 34271171 [TBL] [Abstract][Full Text] [Related]
12. Sequentially degradable hydrogel-microsphere loaded with doxorubicin and pioglitazone synergistically inhibits cancer stemness of osteosarcoma. Cao J; Du X; Zhao H; Zhu C; Li C; Zhang X; Wei L; Ke X Biomed Pharmacother; 2023 Sep; 165():115096. PubMed ID: 37421781 [TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-Loaded Microalgal Delivery System for Combined Chemotherapy and Enhanced Photodynamic Therapy of Osteosarcoma. An X; Zhong D; Wu W; Wang R; Yang L; Jiang Q; Zhou M; Xu X ACS Appl Mater Interfaces; 2024 Feb; 16(6):6868-6878. PubMed ID: 38294964 [TBL] [Abstract][Full Text] [Related]
14. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22. Zhu K; Yuan Y; Wen J; Chen D; Zhu W; Ouyang Z; Wang W Aging (Albany NY); 2020 Apr; 12(8):6644-6666. PubMed ID: 32302291 [TBL] [Abstract][Full Text] [Related]
15. A conductive gelatin methacrylamide hydrogel for synergistic therapy of osteosarcoma and potential bone regeneration. Liu X; Zhang Y; Wu H; Tang J; Zhou J; Zhao J; Wang S Int J Biol Macromol; 2023 Feb; 228():111-122. PubMed ID: 36563819 [TBL] [Abstract][Full Text] [Related]
16. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma. Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354 [TBL] [Abstract][Full Text] [Related]
17. Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis. Wei H; Chen F; Chen J; Lin H; Wang S; Wang Y; Wu C; Lin J; Zhong G Int J Nanomedicine; 2022; 17():3483-3495. PubMed ID: 35959282 [TBL] [Abstract][Full Text] [Related]
18. Has_circ_0010220 regulates the miR-574-3p/IL-6 axis to increase doxorubicin resistance in osteosarcoma. Gu Y; Wang G; Ran B Hum Exp Toxicol; 2022; 41():9603271221131307. PubMed ID: 36250452 [TBL] [Abstract][Full Text] [Related]
19. Local release of gemcitabine via in situ UV-crosslinked lipid-strengthened hydrogel for inhibiting osteosarcoma. Wu W; Dai Y; Liu H; Cheng R; Ni Q; Ye T; Cui W Drug Deliv; 2018 Nov; 25(1):1642-1651. PubMed ID: 30799654 [TBL] [Abstract][Full Text] [Related]
20. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma. Qiu R; Sun D; Bai Y; Li J; Wang L Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]